|
New breakout alert on Cannabis Science, Inc. (CBIS)
Last time we saw CBIS dip down to these levels it had a nice bounce up to the .04c range. Keep a close eye on CBIS and do your research before tomorrow.
Quote: www.finance.yahoo.com/q?s=CBIS
Website: www.cannabisscience.com
Major news was released last week. I am shocked we saw the market come off.
CBIS is one active company that continues to release big news and trade large volume. One thing about CBIS is that we could see big swings in very little time.
News Release:
Cannabis Science to Begin Its Drug Development Program With IGXBio and Its GenePro(R), DNA-Based Immunotherapeudic, FDA IND # Approved
CBIS also released this as a bonus to all shareholders:
Cannabis Science Positions Itself to Issue Dividend Payouts to Its Shareholders
CBIS works with leading experts in drug development, medicinal characterization and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of illnesses caused by infections as well as for age-related illness. The Company’s initial focus is on skin cancers and neurological conditions.
Now while there may be quite a few MJ startups playing games out there, CBIS seems to be the real deal. Just take a look at this WSJ article “Pot Industry Puts on a Tie” released earlier this month, spotlighting the Chief Financial Officer at CBIS, Robert Kane.
Now that is about as big of a deal as it gets.
What we may be looking at is the next Boon market. Startups in the MJ sector could soon be touting Bln Dlr IPO’s and numbers like this show why; MarijuanaIndex(dot)org lists over 40 publicly traded companies in the industry, with a combined market capitalization of nearly 4Bln Dlrs.
The MJ market is quickly becoming Big Business, there is a race happening right now to find out who ends up on top and with the way it is looking CBIS certainly appears to hold a lot of of the cards right now.
To get an idea on just how enormous this market is and the potential it has to transform these small market companies just look at these figures:
• According to government surveys, some 25M Americans have smoked MJ in the past year, and more than 14M Americans do so on a regular basis.
• Studies have shown the MJ market could be valued at a staggering 120Bln Dlrs.
• The public is trending towards legalization. In a Pew Research Center poll, a majority of Americans (52%) favored legalization, the first time that threshold has been reached since polling began on that issue back in 1969.
• With 2.4M Med-MJ patients in the U.S. this market is already absolutely enormous and with the direction the Country is moving things are only getting larger.
• A budget proposal from Colorado Gov. estimates MJ sales would reach approximately 610M next fiscal year.
The market for Med MJ has exploded in recent years with many states reporting massive growth. From a recent survey, sales from MJ stores in the Los Angeles area alone are estimated at 3Bln Dlrs per year, and maybe even more.
Considering the size of the L.A. market alone, the national market could reach as high as 100 Bln Dlrs.
Now in case you haven’t heard the news yet… New York has become the latest state to permit the use of Med-MJ. In doing so Gov. Andrew Cuomo has opened one of the largest marketplaces to companies focused on medical grade MJ treatments.
In addition to several recent announcements of clinical trials and other research surrounding their proprietary formulations of cannabinoid treatments, the Company has also made waves with its financial postings.
In its fiscal year ending March 31st, CBIS has tripled its Total Assets and lowered its net losses by nearly 2/3rds, all the while raising sufficient capital to use to invest in its pre-clinical drug development.
The Company has also recently signed a distribution agreement with MDS, which is owned by Medbox Inc., that will garner the company half the gross profits on MDS equipment sold in markets across nearly every continent on earth. In addition, a unique partnership with Dutch cannabis company Mediwiet will enable CBIS to conduct one of the world’s largest observational studies on medicinal cannabis-based medicine.
With landmark legislation opening up new, untapped markets seemingly every month, CBIS couldn’t ask for much more…
… so get started on researching this exciting young MedMJ company right away.
Remember, we always encourage you to do further research. Never take our word for it, read our disclaimer to see why, and of course always consult a professional.
Just because a situation looks great things can still go wrong and often do. Be smart and protect yourself.
Enjoy your evening,
www.TryBestPennyStocks.biz
*Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.*
The disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE WELL: The TBPS employees are not registered as an Investment Advisor in any jurisdiction whatsoever. This is a Paid Advertisement.
Full disclaimer can be read at http://trybestpennystocks.biz/disclaimer.php
Release of Liability: Through use of this website viewing or using you agree to hold TBPS, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TBPS affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. TBPS encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TBPS makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to buy or sell any securities. Any claims or Statements should be deemed apocryphal. TBPS, nor any of its affiliates are not registered investment advisors or broker dealers.
The profiles are a service of TBPS a marketing and advertising firm that may have been compensated. All direct and third party compensation received will be disclosed within each individual alert in accordance with section 17(b) of the nineteen thirty three Securities Act. Any compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.
TBPS and /or its affiliates may buy, hold, and sell securities in the companies profiled. When compensated in shares, all readers should be aware that it is our policy to liquidate all shares immediately. We reserve the right to buy or sell the shares of any of the companies mentioned in any materials we produce at any time. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled companies.
We have received fifteen hundred dollars by a third party,for a two-day marketing campaign of CBIS.
We have aleady received onethousand dollars by a third party,for a two-day marketing campaign of CBIS which has expired.
We have already received onethousand dollars by a third party,for a two-day marketing campaign of CBIS which has expired.
We do not own any shares or hold any positions in cbis.
The third party may have shares and may liquidate them, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company.
|
